Far Infrared Irradiation for Managing, Control and Treatment of Huntington's Disease (HD)
This trial is active, not recruiting.
|Treatment||far infrared radiation|
|Sponsor||GAAD Medical Research Institute Inc.|
|Start date||May 2008|
|End date||May 2010|
|Trial size||5 participants|
|Trial identifier||NCT00675077, GAAD-HD-CTP1|
Huntington's disease (HD) is a fatal disease with profound neurological and behavioral features. HD is typically characterized by uncontrollable movements and psychological disturbances.
This study will investigate the use of far infrared radiation for control, management and treatment of HD.
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
Treatment of people with HD
time frame: 2 years
Rehabilitation of people with HD
time frame: 2 Years
Male or female participants of any age.
Inclusion Criteria: - People with HD Exclusion Criteria: - None
|Official title||Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Control, Management and Treatment of HD|
|Principal investigator||Ken Nedd, M.D.|
|Description||Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells. It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have HD.|
Call for more information